Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


When Patients With Chronic HBV Infection Do Not Meet Indications for Immediate Treatment: The Critical Role of Ongoing Monitoring

In this podcast, CCO’s expert faculty discusses how to identify which patients with chronic HBV infection may not need immediate HBV treatment and the critical need to continue monitoring such patients even in the absence of ongoing therapy.
person default
Pietro Lampertico, MD, PhD
Released: May 26, 2022

In this episode, Pietro Lampertico, MD, PhD, discusses what to do when treatment for hepatitis B virus (HBV) infection is not indicated, covering topics such as:

  • The different phases of chronic HBV infection
  • Which patients in different phases require immediate HBV treatment and which can be monitored without therapy
  • The critical importance of ongoing monitoring for patients who do not meet indications for immediate therapy
  • The tests and frequency that should be used for monitoring patients not receiving HBV treatment

Information on this Educational Activity


Pietro Lampertico, MD, PhD

Professor of Gastroenterology
Director, Division of Gastroenterology and Hepatology
IRCCS Ca Granda Policlinico Hospital
University of Milan
Milan, Italy

Pietro Lampertico, MD, PhD, has disclosed that he has received consulting fees from AbbVie, Aligos, Antios, Eiger, Gilead Sciences, GlaxoSmithKline, Janssen, and Myr Pharma.

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.

Related Content

Clinical Care Options (CCO) expert audio: Dr Carla Coffin discusses investigational HBV cure strategies

person default Carla Coffin, MD Released: June 30, 2022

Clinical Care Options (CCO) commentary from a patient who shares their experience of severe liver disease from HBV/HDV coinfection

person default Joaquín (Patient) Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: June 29, 2022 Expired: June 28, 2023

Patient perspectives and key action items to address in clinical settings to reduce HBV care barriers in the United States, from Clinical Care Options (CCO)

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD Jennifer Wild, MS, BSN, RN, OCN Released: June 22, 2022

Clinical Care Options (CCO) commentary from Dr Carla Coffin on risks vs benefits of treating patients in the indeterminate category for HBV treatment

person default Carla Coffin, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: June 21, 2022 Expired: June 20, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings